|
NIPBL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62736490949555E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.69624339416441E-13 |
| Normal-vs-Stage2 |
8.71030000348938E-08 |
| Normal-vs-Stage3 |
3.54429818827384E-11 |
| Normal-vs-Stage4 |
2.00894856305922E-12 |
| Stage1-vs-Stage2 |
9.007800E-01 |
| Stage1-vs-Stage3 |
2.012800E-01 |
| Stage1-vs-Stage4 |
2.006200E-02 |
| Stage2-vs-Stage3 |
4.848200E-01 |
| Stage2-vs-Stage4 |
1.492590E-01 |
| Stage3-vs-Stage4 |
3.838200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.91988655476416E-14 |
| Normal-vs-AfricanAmerican |
1.99800999999278E-05 |
| Normal-vs-Asian |
8.35589997194575E-09 |
| Caucasian-vs-AfricanAmerican |
6.596400E-01 |
| Caucasian-vs-Asian |
5.325200E-01 |
| AfricanAmerican-vs-Asian |
9.520800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.41020528587887E-11 |
| Normal-vs-Female |
1.63824509513688E-12 |
| Male-vs-Female |
3.379800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.52446977053478E-12 |
| Normal-vs-Age(41-60Yrs) |
1.29479760246909E-11 |
| Normal-vs-Age(61-80Yrs) |
1.89048776633172E-12 |
| Normal-vs-Age(81-100Yrs) |
1.895230E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.577400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.811050E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.926600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.773400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.986200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.094000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.432100E-04 |
| Classical-VS-Follicular |
1.153830E-01 |
| Classical-VS-Other |
9.374200E-01 |
| Classical-VS-Normal |
4.61475302415693E-12 |
| Tall-VS-Follicular |
4.213800E-02 |
| Tall-VS-Other |
7.246200E-02 |
| Tall-VS-Normal |
7.89257548206024E-13 |
| Follicular-VS-Other |
6.017400E-01 |
| Follicular-VS-Normal |
7.9132000951887E-10 |
| Other-VS-Normal |
1.448110E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.00586206031039E-13 |
| Normal-vs-N1 |
5.0487000025079E-08 |
| N0-vs-N1 |
8.690400E-01 |
|
|
